Silverarc Capital Management
Silverarc Capital Management reported 65 stocks worth $899M in its 13F filing for Q2 2026, filed Aug 13, 2026. Its largest holdings are ASND (6.1%), CELC (5.8%) and COGT (5.5%). Compared with Q1 2026, the fund opened new positions in ASND, ELVN and SGMT, added to CELC, IMNM and RYTM, trimmed COGT, URGN and DNTH and sold out of ASND, SRRK and CGON.
Holdings
| # | Stock | Value | Weight | Shares | Change | Shares, 8 qtrs | Held |
|---|---|---|---|---|---|---|---|
| 1 |  ASND Ascendis Pharma A/s | $55M | 6.1% | 206K | New position | 1 of 8 | |
| 2 |  CELC Celcuity Inc | $52.4M | 5.8% | 501K | +143K (+40%) | 4 of 8 | |
| 3 |  COGT Cogent Biosciences Inc | $49.6M | 5.5% | 1.3M | −33K (−3%) | 6 of 8 | |
| 4 |  URGN Urogen Pharma Ltd | $47.9M | 5.3% | 1.3M | −201K (−13%) | 8 of 8 | |
| 5 |  IMNM Immunome Inc | $42.7M | 4.8% | 2M | +167K (+9%) | 3 of 8 | |
| 6 |  DNTH Dianthus Therapeutics Inc | $38M | 4.2% | 390K | −265K (−40%) | 6 of 8 | |
| 7 |  RYTM Rhythm Pharmaceuticals Inc | $34.6M | 3.9% | 311K | +5,461 (+2%) | 8 of 8 | |
| 8 |  ORKA Oruka Therapeutics Inc | $33.6M | 3.7% | 353K | +202K (+134%) | 3 of 8 | |
| 9 |  GLUE Monte Rosa Therapeutics Inc | $26.8M | 3.0% | 1.1M | −894K (−45%) | 4 of 8 | |
| 10 |  SNDX Syndax Pharmaceuticals Inc | $26.5M | 3.0% | 1.2M | +325K (+37%) | 8 of 8 |
Positions at Jun 30, 2026, as reported. Change is against the fund's Q1 2026 filing; weight is the share of the fund's reported stocks.
Sold out
held in Q1 2026, gone in Q2 2026| Stock | Value last quarter | Shares sold |
|---|---|---|
KALVISTA PHARMACEUTICALS INC | $57.9M | 2.9M |
NUVALENT INC | $36.4M | 355K |
ASND Ascendis Pharma A/s | $28.5M | 125K |
CENTESSA PHARMACEUTICALS PLC | $18.5M | 466K |
 SRRK Scholar Rock Hldg Corp | $16.7M | 340K |
🔒 Free account: see all 22.
Options
valued at the underlying shares| Stock | Type | Value | Shares | Change |
|---|---|---|---|---|
 ARKK ARK ETF TR | Put | $21M | 500K | +500,000 |
SNDX Syndax Pharmaceuticals Inc | Call | $15.2M | 694K | +373,600 |
 ORIC Oric Pharmaceuticals Inc | Call | $7.4M | 683K | +682,600 |
GLUE Monte Rosa Therapeutics Inc | Call | $7.3M | 300K | +300,000 |
 ABVX Abivax SA | Call | $6.7M | 50K | +50,000 |
🔒 Free account: see all 8.
Reported value
last 8 quartersThe value of the US stocks the fund reported, at quarter end prices. It moves with the market as well as with buying and selling.
Filings for Q2 2026
straight from the SEC| Filed | Form | Quarter | |
|---|---|---|---|
| Aug 13, 2026 | 13F-HR | Q2 2026 | SEC filing ↗ |
Other superinvestors
All hedge fund holdings →Silverarc Capital Management 13F FAQ
What does Silverarc Capital Management own?
Silverarc Capital Management reported 65 stocks worth $899M in its 13F filing for Q2 2026, filed Aug 13, 2026. Its largest holdings are ASND (6.1%), CELC (5.8%) and COGT (5.5%). The table above lists every position in the filing (the top 10 without an account).
What did Silverarc Capital Management buy and sell in Q2 2026?
Compared with Q1 2026: 20 new positions, 15 added to, 27 trimmed and 22 sold out. New positions include ASND, ELVN and SGMT. It sold all of ASND, SRRK and CGON.
When will Silverarc Capital Management file its next 13F?
Holdings as of Sep 30, 2026 are due by Nov 16, 2026. The filing appears on this page within minutes of reaching the SEC.
How much is Silverarc Capital Management's portfolio worth?
The Q2 2026 filing reports $899M in US stocks ($962M including options). That leaves out cash, bonds, short positions and most foreign holdings, so the fund's total assets are usually larger.
For informational and educational purposes only. Not investment advice, and not a recommendation to buy or sell any security. Holdings come from the fund's SEC Form 13F filings as reported and show positions at the end of the quarter, up to 45 days before the filing. The fund may have changed its positions since. A 13F leaves out short positions, cash, bonds and most foreign holdings. See all hedge fund holdings.